Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LARTRUVO vs CLOLAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Olaratumab is a recombinant human Ig G1 monoclonal antibody that binds to platelet-derived growth factor receptor alpha (PDGFRα), blocking PDGF-AA, -BB, and -CC binding and receptor activation, thereby inhibiting tumor growth.
Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.
Treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery, in combination with doxorubicin.
FDA: Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years.,Off-label: Treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic myeloid leukemia (CML) in blast crisis.
10 mg/kg IV every 2 weeks until disease progression or unacceptable toxicity.
5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.
Terminal elimination half-life is approximately 11 days (range 4–20 days), supporting a 3-week dosing interval when combined with doxorubicin.
Terminal elimination half-life approximately 5.2 hours in patients with normal renal function; prolonged in renal impairment (up to 9.8 hours with Cr Cl <60 m L/min) and in elderly; clinical context: supports once-daily dosing adjustment for renal function.
Olaratumab is a monoclonal antibody expected to be degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways identified.
Clofarabine is partially metabolized by deamination via cytidine deaminase (CDA) to inactive 6-keto-clofarabine. Approximately 50-60% of the drug is excreted unchanged in urine.
Olaratumab is cleared primarily via proteolytic catabolism; no specific renal or biliary excretion studies have been conducted. In patients, only trace amounts are excreted in urine (<1% of dose).
Renal: 50-60% as unchanged drug; biliary/fecal: minimal (<5%)
Approximately 90% bound to plasma proteins (primarily Ig G, as a monoclonal antibody).
47% bound to human plasma proteins, primarily albumin.
Central volume of distribution is approximately 4.1 L (0.058 L/kg for a 70 kg patient), indicating limited extravascular distribution, consistent with a large monoclonal antibody.
Central Vd approximately 172 L/m² (extensive tissue distribution); in L/kg: ~4.6 L/kg (assuming 70 kg patient with BSA 1.73 m²). Clinical meaning: indicates wide distribution into total body water and tissues, exceeding total body water.
100% (intravenous administration only; not bioavailable orally).
Intravenous: 100% (only route of administration); oral: not available (no oral formulation).
No dose adjustment required for mild to moderate renal impairment (CLcr 30-89 m L/min). Not studied in severe renal impairment (CLcr <30 m L/min) or end-stage renal disease; use only if benefit outweighs risk.
Cr Cl >= 60 m L/min: no adjustment. Cr Cl 30-59 m L/min: reduce dose by 20%. Cr Cl < 30 m L/min: contraindicated.
Mild hepatic impairment (Child-Pugh A): no adjustment. Moderate or severe (Child-Pugh B or C): not studied; use only if benefit outweighs risk.
No specific guidelines; use caution in severe hepatic impairment (Child-Pugh class C) and consider dose reduction based on tolerability.
Safety and efficacy not established in pediatric patients; no recommended dose.
1-21 years: 5 mg/m2 IV over 2 hours daily for 5 days every 28 days; reduce dose by 50% in patients with renal impairment.
No dose adjustment based on age; monitor for adverse reactions more frequently due to higher incidence of underlying renal or hepatic impairment and comorbidities.
No specific dose adjustment, but monitor renal function closely due to age-related decline and increased risk of toxicity.
WARNING: INFUSION-RELATED REACTIONS (IRRs), INCLUDING DEATH. Serious and sometimes fatal infusion-related reactions can occur. Premedicate and monitor during infusion. Interrupt or permanently discontinue based on severity.
WARNING: HEMATOLOGIC TOXICITY, INFECTION, AND HEPATIC TOXICITY. Clolar suppresses bone marrow function, causing severe neutropenia, thrombocytopenia, and anemia. Fatal infections have occurred. Hepatic toxicity, including hepatic failure and death, has been reported. Monitor blood counts and liver function frequently.
Infusion-related reactions (including severe and fatal); embryo-fetal toxicity; neutropenia; cardiotoxicity (left ventricular dysfunction); and increased adverse reactions in patients with baseline left ventricular ejection fraction (LVEF) below normal.
Bone marrow suppression: severe neutropenia, thrombocytopenia, and anemia require close monitoring. Infections: serious and fatal infections (bacterial, fungal, viral) may occur. Hepatic toxicity: elevation of liver enzymes, bilirubin, and hepatic veno-occlusive disease. Renal toxicity: increased creatinine, hematuria, and hemolytic uremic syndrome-like reactions. Cardiac toxicity: pericardial effusion, hypotension, and ventricular dysfunction. Tumor lysis syndrome. Hypersensitivity reactions. Use in pregnancy: embryo-fetal toxicity. Vaccination: avoid live vaccines.
None known.
Absolute: Hypersensitivity to clofarabine or any component of the formulation. Relative: Severe hepatic impairment (bilirubin >3 mg/d L or transaminases >5x ULN). Severe renal impairment (creatinine clearance <30 m L/min).
No specific food interactions known. However, doxorubicin may cause nausea and vomiting; advise taking antiemetics as prescribed and eating small, frequent meals. Avoid grapefruit and grapefruit juice as they may affect CYP3A4 metabolism of doxorubicin.
No specific food interactions are documented. However, maintain adequate hydration to reduce risk of nephrotoxicity and tumor lysis syndrome. Avoid grapefruit and grapefruit juice as they may affect metabolism via CYP3A4 (theoretical concern, though clofarabine is primarily renally excreted).
Based on its mechanism of action (PDGFR-alpha inhibitor) and animal studies, LARTRUVO (olaratumab) is expected to cause fetal harm when administered to pregnant women. There are no adequate human data. In animal reproduction studies, administration of olaratumab to pregnant monkeys during organogenesis resulted in embryofetal toxicity including increased abortion and fetal anomalies. Use is contraindicated in pregnancy; advise females of reproductive potential to use effective contraception during treatment and for at least 3 months after the last dose. Risks apply throughout all trimesters.
Clofarabine is contraindicated in pregnancy. Based on its mechanism of action (inhibitor of DNA synthesis) and animal studies, there is a high risk of fetal harm if administered during pregnancy. In the first trimester, there is a significant risk of embryolethality and teratogenicity (structural anomalies). In the second and third trimesters, fetal growth restriction and central nervous system damage may occur. Pregnancy must be excluded before initiation.
No data on the presence of olaratumab in human milk, effects on the breastfed infant, or milk production. Due to the potential for serious adverse reactions, advise women not to breastfeed during treatment and for at least 3 months after the last dose. M/P ratio is unknown.
No data available on the excretion of clofarabine into breast milk or its effects on the nursing infant. Due to potential for serious adverse reactions (e.g., myelosuppression, gastrointestinal toxicity), breastfeeding is contraindicated during therapy and for at least 3 months after the last dose. M/P ratio is unknown.
LARTRUVO is contraindicated in pregnancy. No dose adjustments during pregnancy have been studied. Pharmacokinetics may alter due to pregnancy-induced changes in volume of distribution, protein binding, and clearance; however, no specific dose adjustment guidelines exist. If treatment is absolutely necessary in a pregnant patient (which is not recommended), consider therapeutic drug monitoring if feasible.
There are no established dose adjustments for clofarabine during pregnancy, as use is contraindicated. Physiological changes in pregnancy (e.g., increased plasma volume, altered renal clearance) may affect pharmacokinetics, but no dosing guidelines exist. If inadvertent exposure occurs, immediate discontinuation is recommended and the pregnancy should be managed by a maternal-fetal medicine specialist.
LARTRUVO (olaratumab) is a PDGFRα inhibitor used in combination with doxorubicin for advanced soft tissue sarcoma not amenable to surgery or radiotherapy. Monitor for infusion-related reactions and pre-medicate with antihistamines and corticosteroids. Assess cardiac function via echocardiogram or MUGA scan before each cycle due to doxorubicin cardiotoxicity. Neutropenia is common; monitor CBCs before each cycle and hold for ANC <1000/mm3. Olaratumab does not require dose adjustment for mild to moderate hepatic impairment but avoid in severe impairment. No dose adjustment for renal impairment. Pregnancy category D: advise effective contraception during and for 3 months after treatment.
Clolar (clofarabine) is a purine nucleoside analog indicated for pediatric relapsed/refractory acute lymphoblastic leukemia. Key pearls: (1) Monitor for systemic inflammatory response syndrome (SIRS) and capillary leak syndrome; premedicate with corticosteroids. (2) Requires aggressive hydration and allopurinol for tumor lysis prophylaxis. (3) Dose reductions needed for renal impairment (Cr Cl < 60 m L/min). (4) Avoid live vaccines during and after treatment.
This medication is given as an intravenous infusion over 60 minutes on Day 1 and Day 8 of each 21-day cycle.,You will receive it together with another chemotherapy drug called doxorubicin.,Common side effects include nausea, fatigue, low white blood cell counts, and infusion-related reactions (fever, chills, shortness of breath).,Report any signs of infection (fever, sore throat) or unusual bleeding/bruising immediately.,Avoid pregnancy and breastfeeding while on this treatment; use effective birth control during and for 3 months after the last dose.,Do not take any other medications, supplements, or herbal products without consulting your doctor.
Clolar is a chemotherapy drug used to treat a type of leukemia in children that has not responded to other treatments.,You may experience side effects like fever, nausea, vomiting, diarrhea, and skin rashes. Report any signs of infection or unusual bleeding.,Drink plenty of fluids as directed to prevent kidney problems. You may receive IV fluids before and after treatment.,Avoid vaccinations without doctor approval, as live vaccines are not safe during treatment.,This drug can cause severe reactions including organ inflammation and fluid retention; seek immediate medical help if you have difficulty breathing, rapid weight gain, or swelling.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LARTRUVO vs CLOLAR, answered by our medical review team.
LARTRUVO is a Antineoplastic Agent that works by Olaratumab is a recombinant human Ig G1 monoclonal antibody that binds to platelet-derived growth factor receptor alpha (PDGFRα), blocking PDGF-AA, -BB, and -CC binding and receptor activation, thereby inhibiting tumor growth.. CLOLAR is a Antineoplastic Agent that works by Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LARTRUVO and CLOLAR depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LARTRUVO is: 10 mg/kg IV every 2 weeks until disease progression or unacceptable toxicity.. The standard adult dose of CLOLAR is: 5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LARTRUVO and CLOLAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LARTRUVO is classified as Category C. Based on its mechanism of action (PDGFR-alpha inhibitor) and animal studies, LARTRUVO (olaratumab) is expected to cause fetal harm when administered to pregnant women. There are no. CLOLAR is classified as Category C. Clofarabine is contraindicated in pregnancy. Based on its mechanism of action (inhibitor of DNA synthesis) and animal studies, there is a high risk of fetal harm if administered du. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.